Home > Dermatology > SPIN 2019 > Novel Considerations > Sustained and complete responses from the phase 3 AMAGINE-2 and -3 studies

Sustained and complete responses from the phase 3 AMAGINE-2 and -3 studies

Expert
Prof. LluĂ­s Puig, Hospital de la Santa Creu i Sant Pau, Spain
Conference
SPIN 2019
Trial
Phase 3, AMAGINE

A post-hoc analysis of the phase 3 AMAGINE-2 and AMAGINE-3 trials including 3,712 people with moderate-to-severe psoriasis showed that 90% of patients treated with brodalumab who achieved Psoriasis Area and Severity Index (PASI) score of 100 also experienced a sustained PASI-100 score [1].

In the same analysis, only 77% of patients treated with ustekinumab who achieved PASI-100 also experienced sustained PASI-100. The authors measured sustained PASI-100 as the time to inadequate response, based on a static physician’s global assessment (sPGA) of ≥3 or persistent values of 2 over at least a 4-week period or after week 16. Since the subpopulations of patients treated with brodalumab and ustekinumab in these studies had different baseline characteristics, the authors did not apply statistical comparisons.
...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on